This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
User:Dora Bonadio/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
<!-- This is a default text for your page '''Dora Bonadio/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. --> | <!-- This is a default text for your page '''Dora Bonadio/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. --> | ||
The Mpro protease (also known as 3CLpro), is a viral non structural protein from the virus SARS-CoV-2 <ref name="Crystal_structure">PMID:32198291</ref>, responsible for a major outbreak of the disease called COVID-19, declared pandemic by WHO in 11 march 2020 <ref name="WHO">WHO. COVID-19 situation reports [Internet]. [cited 2020 May 15]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports | The Mpro protease (also known as 3CLpro), is a viral non structural protein from the virus SARS-CoV-2 <ref name="Crystal_structure">PMID:32198291</ref>, responsible for a major outbreak of the disease called COVID-19, declared pandemic by WHO in 11 march 2020 <ref name="WHO">WHO. COVID-19 situation reports [Internet]. [cited 2020 May 15]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports | ||
| - | </ref>. It has an important role in virus replication, as it’s responsible for cleavage of the polyproteins of the virus, alongside with papain-like protease(s) (3). | + | </ref>. It has an important role in virus replication, as it’s responsible for cleavage of the polyproteins of the virus, alongside with papain-like protease(s) <ref name="sars_mers">PMID:25039866</ref>(3). |
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | ||
== Function == | == Function == | ||
| - | The Mpro protein function is mainly deduced from the function of SARS-CoV virus Mpro , which has a 96% amino acid identity and a highly similar three-dimensional structure with SARS-CoV-2 Mpro <ref name="Crystal_structure" />. As a protease, Mpro is an enzyme that causes proteolysis, which means that it breaks protein peptide bonds by hydrolysis (4). Indeed, the Mpro processes the replicase polyprotein 1ab (pp1ab ~790 kDa) translated from the viral RNA ORF1ab <ref name="Crystal_structure" />(1, 5). In fact, Mpro cleaves 11 sites of pp1ab and the recognition sequence at most sites is between Leu-Gln and (Ser, Ala, Gly) <ref name="Crystal_structure" />(1, 3). Proteins resulting from this polyprotein cleavage are non-structural proteins (NSPs) and they seem to contribute with viral replication and transcription (5). Thus, by processing an important number of non-structural proteins, this enzyme plays a critical role in SARS-CoV-2 replication. | + | The Mpro protein function is mainly deduced from the function of SARS-CoV virus Mpro , which has a 96% amino acid identity and a highly similar three-dimensional structure with SARS-CoV-2 Mpro <ref name="Crystal_structure" />. As a protease, Mpro is an enzyme that causes proteolysis, which means that it breaks protein peptide bonds by hydrolysis (4). Indeed, the Mpro processes the replicase polyprotein 1ab (pp1ab ~790 kDa) translated from the viral RNA ORF1ab <ref name="Crystal_structure" />(1, 5). In fact, Mpro cleaves 11 sites of pp1ab and the recognition sequence at most sites is between Leu-Gln and (Ser, Ala, Gly) <ref name="Crystal_structure" /><ref name="sars_mers" />(1, 3). Proteins resulting from this polyprotein cleavage are non-structural proteins (NSPs) and they seem to contribute with viral replication and transcription (5). Thus, by processing an important number of non-structural proteins, this enzyme plays a critical role in SARS-CoV-2 replication. |
| Line 22: | Line 22: | ||
== Structural comparison with SARS-CoV M<sup>pro</sup> == | == Structural comparison with SARS-CoV M<sup>pro</sup> == | ||
| - | As have been shown, because of its importance for viral replication, inhibiting SARS-CoV-2 Mpro activity could lead to viral replication blockage <ref name="Crystal_structure" />(1, 6). Moreover, no human proteases has been reported to have a similar cleavage specificity and so, in this aspect, Mpro inhibitors toxic side-effects may be reduced (3). Therefore, CoV Mpro has been an attractive drug target among coronaviruses (3) and so it is for COVID-19 <ref name="Crystal_structure" />(1, 6). Indeed, virtual drug screening, structure-assisted drug design, and high-throughput screening are been used to repurpose approved pharmaceutical drug and drug candidates targeting SARS-CoV-2 Mpro (6, 8) . Furthermore, a study carrying the pharmacokinetic characterization of an optimized Mpro α-ketoamide inhibitor provides useful framework for development of this kind of inhibitors toward coronaviruses <ref name="Crystal_structure" />. It was showed that the α-ketoamide inhibitor interacts with the catalytic site of the enzyme through two hydrogen bonding interactions, as can be seen in the complex formed between SARS-CoV-2 Mpro and an α-ketoamide inhibitor <ref name="Crystal_structure" />. | + | As have been shown, because of its importance for viral replication, inhibiting SARS-CoV-2 Mpro activity could lead to viral replication blockage <ref name="Crystal_structure" />(1, 6). Moreover, no human proteases has been reported to have a similar cleavage specificity and so, in this aspect, Mpro inhibitors toxic side-effects may be reduced <ref name="sars_mers" />(3). Therefore, CoV Mpro has been an attractive drug target among coronaviruses <ref name="sars_mers" />(3) and so it is for COVID-19 <ref name="Crystal_structure" />(1, 6). Indeed, virtual drug screening, structure-assisted drug design, and high-throughput screening are been used to repurpose approved pharmaceutical drug and drug candidates targeting SARS-CoV-2 Mpro (6, 8) . Furthermore, a study carrying the pharmacokinetic characterization of an optimized Mpro α-ketoamide inhibitor provides useful framework for development of this kind of inhibitors toward coronaviruses <ref name="Crystal_structure" />. It was showed that the α-ketoamide inhibitor interacts with the catalytic site of the enzyme through two hydrogen bonding interactions, as can be seen in the complex formed between SARS-CoV-2 Mpro and an α-ketoamide inhibitor <ref name="Crystal_structure" />. |
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | ||
Revision as of 02:58, 9 June 2020
SARS-CoV-2 main protease (Mpro)
| |||||||||||
